

Curriculum Vitae

Personal Information

Name: **Timothy G. Beukelman**
Citizenship: U.S.A.
Rank/Title: Associate Professor, Division of Pediatric Rheumatology
Department: Pediatrics
Secondary Appointment: Division of Clinical Immunology and Rheumatology, Department of Internal Medicine
Business Address: University of Alabama at Birmingham /
Children's of Alabama
1600 7th Avenue South
CPP 210
Birmingham, AL 35233-1711
205-996-9191
Email: tbeukelman@peds.uab.edu

Hospital and Other (non-academic) Appointments

2008 – 2013 Alabama Children's Rehabilitation Service, Pediatric Rheumatology

Professional Consultantships

Pediatric Education for Drug Safety (PEDS), University of North Carolina, Chapel Hill
Pediatric rheumatology expert panel member, 2007-2008
Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center Program
Technical Expert Panel member, 2009 – 2010
McKesson Health Solutions
Expert reviewer of specialty pharmaceutical drug use algorithms, 2011, 2013
Novartis
Systemic Juvenile Idiopathic Arthritis Advisory Board, 2012
Canakinumab Phase III Advisory Board, 2012
Systemic Juvenile Idiopathic Arthritis Advisory Board, 2013
Review of educational materials, 2013
Genentech
Polyarticular and Systemic JIA Advisory Board, 2012
Medscape
Development of systemic JIA patient simulation modules, 2013
UCB
Safety Officer, Data Safety Monitoring Board, 2013 –

Education

University of Pennsylvania, Philadelphia, PA	M.S.C.E.	2008
Washington University, Saint Louis, MO	M.D.	2001
University of Illinois, Urbana-Champaign, IL	B.S.	1997

Licensure

Alabama (28137)

Pennsylvania (MD424288) – inactive

Ohio (82203) – inactive

Board Certification

American Board of Pediatrics – Pediatrics, 2004

American Board of Pediatrics – Pediatric Rheumatology, 2009

Post-Doctoral Training:

2004-2007 Fellow in Pediatric Rheumatology, The Children's Hospital of Philadelphia, PA

2002-2004 Resident in Pediatrics, Cincinnati Children's Hospital Medical Center, OH

2001-2002 Intern in Pediatrics, Cincinnati Children's Hospital Medical Center, OH

Academic Appointments

2007-2013 Assistant Professor of Pediatrics, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, AL

2011- Associate Professor of Pediatrics, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, AL

Awards/Honors

2013 ACR/EULAR International Academic Rheumatology Exchange, Early Career Investigator Delegate

2013 Member, American Pediatric Society

2008 – 2014 National Institute of Health (NIH) Loan Repayment Program for Clinical Researchers

2007 University of Alabama Health Services Foundation General Endowment Fund Scholar Award

2005, 2006 Fellows Scholarship Travel Fund, American College of Rheumatology

2005-2006 Ruth L. Kirschstein National Research Service Award (NRSA), National Institutes of Health

2002 Pediatric Rheumatology Residents Program, American College of Rheumatology

1998 Dr. Lee B. and Virginia G. Harrison Scholars Program, Washington University

1997 *Summa Cum Laude*, Phi Beta Kappa, University of Illinois

1997 Highest Distinction for Senior Thesis, University of Illinois

Professional Societies

Society for Pediatric Research, Member 2013 –

International Society for Pharmacoepidemiology, 2011 –

Pediatric Special Interest Group, 2012 –

Society for Clinical and Translational Science, 2009 –

American College of Rheumatology, Fellow 2007 –

ACR/EULAR Exchange, Early Career Investigator Delegate, 2013

Strategic Planning Task Force, 2013

Pediatric Rheumatology Symposium (PRSYM) Planning Committee, 2012 – 2014

2020 Task Force Member, 2011 – 2013

Timothy Beukelman, MD, MSCE

Curriculum Vitae

Page 2

Practice Guidelines Subcommittee Member, 2010 –
Chair, Practice Guidelines Subcommittee, 2013 –
Quality of Care Committee Member, 2013 –
Childhood Arthritis & Rheumatology Research Alliance (CARRA), 2005 –
Juvenile Idiopathic Arthritis Registry Workgroup, 2009
CARRAnet Data/Sample Share Committee, 2012 –
Juvenile Idiopathic Arthritis Research Committee Member, 2005 –
Vice-Chair, JIA Research Committee, 2012 – 2013
Chair, JIA Research Committee, 2013 –
Juvenile Idiopathic Arthritis Protocol Evaluation Subcommittee Chair, 2012 – 2013
Alabama Society for the Rheumatic Diseases, 2007 –
Tri-State (PA, DE, NJ) Pediatric Rheumatology Study Group, 2004-2007
Philadelphia Rheumatism Society, 2004-2007

Memberships

UAB Deep South Musculoskeletal Center for Education and Research on Therapeutics (CERTs)
Investigator, 2007 –
Pediatric Rheumatology Care and Outcome Improvement Network (PR-COIN)
Steering committee member, 2008 – 2012
Pediatric Rheumatology Collaborative Study Group (PRCSG)
Member, 2012 –
UAB Center for Outcomes and Effectiveness Research and Education (COERE)
Member, 2012 –

Councils and Committees

FDA Workshop: “Developing a Consolidated Pediatric Rheumatology Observational Registry”
Session Co-Chair, 2009
Juvenile Idiopathic Arthritis Quality Measures Work Group
Member, 2008 – 2010
Juvenile Idiopathic Arthritis Consolidated Registry (JIA CoRe) Task Force
Executive Committee; Steering Committee
Chair, Registry Design Subcommittee
American College of Rheumatology Practice Guidelines Subcommittee
Member, 2010 –
Chair, 2013 –
CTSA Consortium Child Health Oversight Committee
Member, 2010 –
American College of Rheumatology 2020 Task Force
Member, 2011 – 2013
Lupus Foundation of America
Grant Reviewer, 2011, 2012, 2013
American College of Rheumatology Annual Scientific Meeting Abstract Selection Committee
Reviewer, 2011
American College of Rheumatology Criteria for Appropriateness of Ultrasound in Rheumatology
Task force panel member, 2011
CARRA JIA Protocol Evaluation Subcommittee

Chair, 2012 – 2013
 Member, 2012 –
 CARRAnet Data/Sample Share Committee
 Member, 2012 –
 International Conference on Pharmacoepidemiology and Therapeutic Risk Management
 Abstract Reviewer, 2012
 Poster Walk Leader, 2012
 Swiss National Science Foundation
 Research Proposal Reviewer, 2012
 CARRA JIA Research Committee
 Vice Chair, 2012 – 13
 Chair, 2013 –
 ACR Pediatric Rheumatology Symposium (PRSYM) Planning Committee
 Member, 2012 – 2014
 American College of Rheumatology Strategic Planning Task Force
 Member, 2013
 German Federal Ministry of Education and Research
 Research Proposal Reviewer, 2013
 Dutch Arthritis Association
 Research Proposal Reviewer, 2013
 American College of Rheumatology Quality of Care Committee
 Member, 2013 –

University Activities

Poster Judge, Medical Student Research Day, 2008
 Reviewer, Kaul Pediatric Research Institute grants, 2010

Editorial Board Memberships

Editorial Board:	Journal of Rheumatology (2012 –
Ad-Hoc Peer Reviewer:	Arthritis & Rheumatism Arthritis Care & Research Arthritis Research & Therapy Journal of Rheumatology Clinical and Experimental Rheumatology Journal of Clinical Rheumatology Pediatric Rheumatology Seminars in Arthritis and Rheumatism Pharmacoepidemiology and Drug Safety Medical Care Value in Health Clinical Journal of the American Society of Nephrology Archives of Disease in Childhood Pediatric Drugs Technology Assessment at Sick Kids (TASK); The Hospital for Sick Children, Toronto, Canada

Major Research Interests

Optimizing the treatment of juvenile idiopathic arthritis using various clinical research methods including retrospective analysis of observational data, prospective observational data collection and analysis, quality improvement, decision analysis, and clinical trials.

Teaching Experience

Educational Lectures:

1. “Juvenile Idiopathic Arthritis”, UAB Rheumatology Fellow Education Conference, October 2012.
2. “Pediatric Vasculitis”, UAB Pediatric Resident Educational Conference, March 2012.
3. “Juvenile Idiopathic Arthritis”, UAB Rheumatology Fellow Educational Conference, October 2011.
4. “Pediatric Vasculitis”, UAB Pediatric Resident Educational Conference, September 2010.
5. “Assorted Rheumatic Disorders”, UAB Pediatric Resident Educational Conference, September 2009.
6. “Pediatric Rheumatology”, UAB Third Year Medical Student Pediatric Clerkship Lecture, (Recurring every 8 weeks) 2008 – 2009.
7. “Juvenile Idiopathic Arthritis”, UAB First Year Medical Student Lecture, May 2008.
8. “Auto-Inflammatory Fever Syndromes”, UAB Rheumatology Fellow Educational Conference, April 2008.
9. “Vasculitis”, UAB Pediatric Resident Educational Conference, February 2008.
10. “Rheumatology in the Pediatric Emergency Department”, UAB Pediatric Emergency Medicine Fellows Educational Conference, October 2007.

Mentoring of Trainees:

1. Robert Richter, UAB Pediatric Hospitalist Fellow, 2013-14. Scholarship Oversight Committee member.
2. Roxanna Sabghi, University of Alabama Medical Student. Scholarly Activity mentor, 2013.
3. Melissa Mannion, UAB Pediatric Rheumatology Fellow, 2011 – 2014. Primary research mentor.
4. Ajay Tramball, University of Alabama Medical Student. Scholarly Activity mentor, 2012. 1 first author publication.
5. Ashley Shafferman, University of Alabama Medical Student. Scholarly Activity mentor 2012. 1 first author publication.
6. Heather Burnett, University of Toronto Health Policy Management and Evaluation Masters of Science Student. External reviewer on Master’s thesis review committee, 2011: “Parents’ Preference for Drug Treatments in Juvenile Idiopathic Arthritis: A Discrete Choice Experiment”.
7. Katherine Donnithorne, University of Alabama Medical Student and Ophthalmology Resident. Recipient of Department of Pediatrics Russell Cunningham Memorial Research Scholars Program, Summer 2008. Award for outstanding poster, Medical Student Research Day, 2008. Scholarly Activity mentor, 2010. Resident research elective mentor, 2012. 3 first author publications.

8. UAB Adult Rheumatology Fellows. Direct supervision and education of adult rheumatology fellows during their required training in pediatric rheumatology.
Fellows trained to date: Allyson McDonough, Maria Danila, Zang Song, Elizabeth Perkins, Bitu Shakoory, Ajoy Chhabra, Bilal Khan, Iris Navarro, Quynh Bao, Rebecca Belsom, Archana Jain, Yong Hwang
9. University of Alabama School of Medicine Summer Health Enrichment Program. Clinical mentor for undergraduate pre-medical students, Summer 2008.

Major Lectures and Visiting Professorships

1. "Juvenile Idiopathic Arthritis: Review and Update". Rheumatology Nurses Society Annual Conference, Nashville, Tennessee, August 2013.
2. "Current Approaches: Role of IL-6 and IL-1 Inhibiting Agents in Systemic JIA Management". Pediatric Rheumatology Workshop, XVII Summit of Pediatricians of Russia, Moscow, Russian Federation, February 2013.
3. "Role of New IL-1 and IL-6 Inhibiting Agents in Systemic Juvenile Idiopathic Arthritis". American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2012.
4. "A New Model for the Assessment of Disease-Specific Pediatric Drug Safety: The Childhood Arthritis and Rheumatology Research Alliance Consolidated Registry (CARRA-CoRe)". International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, August 2012.
5. "Treatment of Juvenile Idiopathic Arthritis". Mexican Congress of Rheumatology, San Luis Potosi, Mexico, February 2012.
6. "The Treatment of Juvenile Idiopathic Arthritis". Mexican College of Rheumatology International Symposium on Rheumatoid Arthritis, Aguascalientes, Mexico, October 2011.
7. "2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis". University of Toronto Intracity Rheumatology Conference, Toronto, Canada, September 2011.
8. "2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis". Danish Pediatric Rheumatology Society Scientific Meeting, Nyborg, Denmark, March 2011.
9. "Malignancy and Juvenile Idiopathic Arthritis: What is the Risk?". Danish Pediatric Rheumatology Society Scientific Meeting, Nyborg, Denmark, March 2011.
10. "Investigating the Incidence of Serious Adverse Events Using Medicaid Billing Data: The Risk of Malignancy and Hospitalized Infection in Juvenile Idiopathic Arthritis". Children's Hospital of Alabama Grand Rounds, Birmingham, Alabama, January 2011.

Grant Support

Current:

1. Agency for Healthcare Research and Quality (AHRQ), U18. Deep South Arthritis and Musculoskeletal Center for Education and Research on Therapeutics (CERTs). Investigator. 2011 – 2016.
2. NIH/NIAMS, L30 (Loan Repayment Program for Clinical Researchers). "Optimizing the Treatment of Childhood Arthritis". Principal Investigator. 2008 – 2010; competitive renewals 2010 – 2012 and 2012 – 2014.

Past:

1. Pfizer. "Usage of NSAIDs, Glucocorticoids, and DMARDs in the Treatment of Juvenile Idiopathic Arthritis in the United States." Principal Investigator. 2012 – 2013.
2. NIH/NCRR (University of Alabama at Birmingham, Center for Clinical and Translational Science), KL2 Mentored Career Development Award. "The Risk of Serious Infection in Juvenile Idiopathic Arthritis". Principal Investigator. 2009 – 2013.
3. NIH/NIAMS (Cincinnati Children's Hospital), P60. Cincinnati Multidisciplinary Clinical Research Center: Improved Understanding of the Biology and Use of TNF Inhibition in Children with JIA. Investigator. 2011 – 2013.
4. NIH/NIAMS (Duke University), ARRA Grand Opportunity. Childhood Arthritis and Rheumatology Research Alliance Network (CARRAnet): Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology. Investigator. 2010 – 2012.
5. Agency for Healthcare Research and Quality (AHRQ), U18. Deep South Musculoskeletal Center for Education and Research on Therapeutics. Investigator. 2009 – 2011.
6. Agency for Healthcare Research and Quality (AHRQ), U18. "Safety Assessment of Anti-TNF Agents Used in Autoimmune Disease". Investigator. 2008-2011.
7. American College of Rheumatology. "Guidelines for the Treatment of Juvenile Idiopathic Arthritis". Principal Investigator. 2009 – 2010.

Volunteer Work

Arthritis Foundation Juvenile Arthritis Family Forum. Guest speaker.
Camp M.A.S.H., Alabama. Volunteer 2007. Camp physician 2010.
Camp JRA, Pennsylvania. Camp physician July 2005.
Saturday Neighborhood Health Center, Washington University. 2000-01.
Young Scientist Program, Washington University. 1997-98.

Bibliography

Manuscripts

Published:

1. Vaid YN, Dunnivant FD, Royal SA, **Beukelman T**, Stoll ML, Cron RQ. Imaging of the temporomandibular joint in juvenile idiopathic arthritis. *Arthritis Care Res*. [published online 19 Sep 2013]
2. Ringold S, Weiss PF, **Beukelman T**, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res* 2013; 65:1551-63.
3. Tramball A, **Beukelman T**, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. *J Rheumatol* 2013; 40:1749-55. [published online 15 Aug 2013]
4. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, **Beukelman T**, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Non-viral opportunistic infections in new users of tumor necrosis factor inhibitor

- therapy: Results of the safety assessment of biologic therapy (SABER) study. *Ann Rheum Dis*. [published online 13 Jul 2013]
5. Donnithorne KJ, Read RW, Lowe R, Weiser P, Cron RQ, **Beukelman T**. Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: A case report. *Pediatr Rheumatol Online J* 2013; 11:25.
 6. Ringold S, **Beukelman T**, Nigrovic PA, Kimura Y. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. *J Rheumatol* 2013; 40:936-42. [published online 15 Apr 2013].
 7. Hurd A, **Beukelman T**. Infectious complications in juvenile idiopathic arthritis. *Curr Rheumatol Rep* 2013; 15:327.
 8. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, **Beukelman T**, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. *JAMA* 2013; 309:887-95. [cited 3 times]
 9. **Beukelman T**, Xie R, Baddley JW, Chen L, Delzell E, Grijalva CG, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Arthritis Rheum* 2013; 65:1384-9. [published online 4 Mar 2013]. [cited 2 times]
 10. Mannion ML, **Beukelman T**. What is the background incidence of malignancy in children with rheumatic disease? *Curr Rheumatol Rep* 2013; 15:310.
 11. Weiss PF, **Beukelman T**, Schanberg LE, Kimura Y, Colbert RA. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison to other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. *J Rheumatol* 2012; 39:2341-51. [published online 15 Oct 2012]. [cited 1 time]
 12. Haynes K, **Beukelman T**, Curtis JR, Herrinton L, Graham D, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune mediated diseases. *Arthritis Rheum* 2013; 65:48-58. [published online 10 Oct 2012]. [cited 3 times]
 13. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattley D, Baddley JW, Liu L, Grijalva CG, Delzell E, **Beukelman T**, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR. Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic therapy (SABER) study. *Am J Ophthalmol* 2013; 155:183-9. [published online 8 Sep 2012]. [cited 2 times]
 14. Mannion ML, Zolak M, Kelly DR, **Beukelman T**, Cron RQ. Sarcoidosis in a young child with Alagille syndrome: A case report. *Pediatr Rheumatol Online J* 2012; 10:32. [published online 31 Aug 2012].
 15. **Beukelman T**, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. *J Rheumatol* 2012; 39:1867-74. [published online 1 Aug 2012]. [cited 3 times]
 16. Saag KG, Mohr PE, Esmail L, Mudano AS, Wright N, **Beukelman T**, Curtis JR, Cutter G, Delzell E, Gary LC, Harrington TM, Karkare S, Kilgore ML, Lewis CE, Moloney R, Oliveira A, Singh J, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon

- DH, Wallace R, Tunis SR. Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. *Contemp Clin Trials* 2012; 33:1211-6. [published online 5 Jul 2012]. [cited 3 times]
17. Woolston SL, **Beukelman T**, Sherry DD. Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility. *Pediatr Rheumatol Online J* 2012; 10:17. [published online 20 Jun 2012]. [cited 1 time]
 18. Stoll ML, Sharpe T, **Beukelman T**, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. *J Rheumatol* 2012; 39:1880-7. [published online 15 May 2012]. [cited 4 times]
 19. **Beukelman T**, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012; 64:2773-80. [published online 8 May 2012]. [cited 9 times]
 20. Curtis JR, Xie F, Chen L, Munter P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, **Beukelman T**, Delzell E. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. *Arthritis Care Res* 2012; 64:1480-9. [published online 3 May 2012]. [cited 5 times]
 21. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, **Beukelman T**, Bridges SL, Chatham WW, Paulus H, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res* 2012; 64:625-39. [cited 120 times]
 22. **Beukelman T**, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012; 64:1263-7. [published online 10 Feb 2012]. [cited 18 times]
 23. DeWitt EM, Kimura Y, **Beukelman T**, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care Res* 2012; 64:1001-10. [published online 30 Jan 2012]. [cited 14 times]
 24. Stoll ML, Good J, Sharpe T, **Beukelman T**, Young D, Waite PD, Cron RQ. Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. *J Oral Maxillofac Surg* 2012; 70:1082-7. [published online 21 Jan 2012]. [cited 6 times]
 25. Bharat A, Xie F, Baddley JW, **Beukelman T**, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. *Arthritis Care Res* 2012; 64:612-5. [published online 12 Dec 2011]. [cited 5 times]

26. Donnithorne KJ, Cron RQ, **Beukelman T**. Attainment of inactive disease status following initiation of TNF α inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease. *J Rheumatol* 2011; 38:2675-81. [published online 15 Nov 2011]. [cited 6 times]
27. Grijalva CG, Chen L, Delzell E, Baddley JW, **Beukelman T**, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA* 2011; 306:2331-9. [published online 6 Nov 2011]. [cited 56 times]
28. Fain ER, Atkinson GP, Weiser P, **Beukelman T**, Cron RQ. Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis. *J Rheumatol* 2011; 38:2272-3. [cited 1 time]
29. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstrom R, **Beukelman T**, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E Patkar NM, Rassen J, Winthrop KL, Nourjah P, Saag KG. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. *Pharmacoepidemiol Drug Saf* 2011; 20:1199-209. [published online 15 Sep 2011]. [cited 10 times]
30. Ashraf AP, **Beukelman T**, Pruneta-Delocche V, Kelly DR, Garg A. Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjögren's syndrome. *J Clin Endocrinol Metab* 2011; 96:3302-7. [published online 31 Aug 2011]. [cited 1 time]
31. Baddley JW, Winthrop KL, Patkar NM, Delzell E, **Beukelman T**, Xie F, Chen L, Curtis JR. Geographic distribution of endemic fungal infections among older persons, United States. *Emerg Infect Dis* 2011; 17:1664-9. [published online 11 Aug 2011]. [cited 13 times]
32. Record JL, **Beukelman T**, Cron RQ. High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. *Pediatr Rheumatol Online J* 2011; 9:20. [cited 1 time]
33. Curtis JR, Xie F, Chen L, Baddley JW, **Beukelman T**, Saag K, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biologic agents. *Ann Rheum Dis* 2011; 70:1401-6. [published online 17 May 2011]. [cited 28 times]
34. **Beukelman T**, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res* 2011; 63:465-82. [cited 96 times]
35. Record JL, **Beukelman T**, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. *J Rheum* 2011; 38:180-1. [cited 12 times]
36. Lovell DJ, Passo MH, **Beukelman T**, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, Morgan DeWitt E, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care. A proposed set of quality measures for the

- process of care in juvenile idiopathic arthritis. *Arthritis Care Res* 2011; 63:10-16. [published online 14 Sep 2010] [cited 9 times]
37. Cron RQ, **Beukelman T**. Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA? [editorial comment]. *Pediatr Rheumatol Online J* 2010; 8:23. [cited 8 times]
 38. Mehta J, Genin A, Brunner M, Scalzi LV, Mishra N, **Beukelman T**, Cron RQ. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis. *Arthritis Rheum* 2010; 62:2499-2509. [published online 6 May 2010]. [cited 5 times]
 39. **Beukelman T**, Saag KG, Curtis JR, Kilgore ML, Pisu M. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. *Osteoporos Int* 2010; 21:1573-84. [published online 24 Nov 2009]. [cited 7 times]
 40. Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, **Beukelman T**, Cron RQ. Rituximab therapy for severe refractory chronic Henoch-Schölein purpura. *J Pediatr* 2009; 155:136-9. [cited 18 times]
 41. Curtis JR, **Beukelman T**, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. *Ann Rheum Dis* 2010; 69:43-7. [published online 15 Jan 2009] *PMCID: PMC2794929* [cited 32 times]
 42. **Beukelman T**, Guevara JP, Albert DA. Optimal treatment of knee monoarthritis in juvenile idiopathic arthritis: a decision analysis. *Arthritis Rheum* 2008; 59:1580-88. [cited 14 times]
 43. **Beukelman T**, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. *Clin Exp Rheumatol* 2008; 26:700-3. [cited 8 times]
 44. Behrens EM, **Beukelman T**, Gallo L, Sprangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania systemic onset juvenile arthritis registry (PASOJAR). *J Rheumatol* 2008; 35:343-8. [cited 21 times]
 45. **Beukelman T**, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. *J Rheumatol* 2007; 34:1918-24. [cited 11 times]
 46. Cahill AM, Cho SS, Baskin KM, **Beukelman T**, Cron RQ, Kaye RD, Towbin RB. Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. *Pediatr Radiol* 2007; 37:544-8. [cited 19 times]
 47. Behrens EM, **Beukelman T**, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. *J Rheumatol* 2007; 34:1133-8. [cited 77 times]
 48. Behrens EM, **Beukelman T**, Cron RQ. Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [letter]. *J Rheumatol* 2007; 34:234. [cited 7 times]

49. **Beukelman T**, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. *J Rheumatol* 2006; 33:2330-6. [cited 23 times]
50. **Beukelman T**, Cron RQ. JIA-associated growth failure and exogenous growth hormone therapy. *Pediatr Rheumatol Online J* 2005; 3:99-108.

In press:

1. Shafferman A, Fontaine KR, Cron RQ, **Beukelman T**. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. *J Rheumatol*. [accepted 19 Aug 2013]
2. Lionetti G, Kimura Y, Schanberg LE, **Beukelman T**, Wallace C, Ilowite N, Winsor J, Fox K, Natter M, Sundry JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman B, Murphy B, Peterson ED, Raymond SC, Setoguchi S, Siegel J, Sobel R, Solomon D, Southwood TR, Vesely R, White P, Wulfraat N, Sandborg CI. Using registries to identify adverse events in rheumatic diseases. *Pediatrics*. [accepted 26 Aug 2013]

Submitted:

1. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, **Beukelman T**, Winthrop K, Baddley JW, Curtis JR. Risk of hospitalized infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
2. Mannion ML, Xie F, Curtis JR, **Beukelman T**. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of TNF inhibitors.

In preparation:

1. Mannion ML, **Beukelman T**. Cancer risk in pediatric rheumatic disease.
2. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, **Beukelman T**, Saag KG, Curtis JR. Persistence with disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Other publications:

1. **Beukelman T**, Cron RQ, Patkar NM, Saag KG, DeWitt EM, Lovell DJ, Ilowite NT, Kimura Y, Laxer RM, Martini A, Ruperto N, Rabinovich CE. Reply [Letter]. *Arthritis Care Res* 2011; 63:1355-6. [cited 3 times]
2. Lovell DJ, Henrickson M, DeWitt EM, Segerman J, Taylor J, Giannini EH, Passo MH, **Beukelman T**, Bowyer SL, Gottlieb BS, Ilowite NT, Kimura Y, Stein LD, Vehe RK. Reply [Letter]. *Arthritis Care Res* 2011; 63:1353.
3. Tolleson-Rinehart S, Morgan DeWitt E, Massie S, **Beukelman T**, Froyum Roise A, Boggan J, Kautz J, Racine C, Olson M, Shores M, Belhorn T, Stein L, Stiles A, Pham V, Goolsby T (of the PEDS Group). Pharmacological Treatment of Juvenile Idiopathic Arthritis: A Pediatric Education for Drug Safety (PEDS) Continuing Education Module. <http://pedscme.unc.edu>. May 1, 2008.

Books

1. **Beukelman T**, Cron RQ, Hanson E. Ankylosing spondylitis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:50-1.
2. **Beukelman T**, Cron RQ. Dermatomyositis/Polymyositis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:262-3.
3. **Beukelman T**, Cron RQ, Hanson E. Diskitis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:282-3.
4. Cron RQ, Weiser P, **Beukelman T**. Juvenile idiopathic arthritis. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology: Principles and Practice, 4th Edition. London: Elsevier; 2013:637-47.

In press:

Published Abstracts

1. Mannion M, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the U.S. and the influence of TNF inhibitors. *Pharmacoepidemiol Drug Saf* 2013; 22 Suppl 1:444.
2. Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E, Curtis JR. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. *Pharmacoepidemiol Drug Saf* 2013; 22 Suppl 1:288.
3. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K, Baddley J, Muntner P, Curtis JR. Comparative safety of biologic agents among Medicare rheumatoid arthritis patients. *Pharmacoepidemiol Drug Saf* 2013; 22 Suppl 1:20.
4. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K. Comparative risks of recurrent hospitalized infection association with biologics in RA patients at high risk. *Pharmacoepidemiol Drug Saf* 2013; 22 Suppl 1:442.
5. Mannion M, Xie F, Curtis JR, **Beukelman T**. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the United States and the influence of TNF inhibitors. *Ann Rheum Dis* 2013; 72(Suppl3):149.
6. Cron RQ, Tramballi A, **Beukelman T**, Weiser P, Atkinson TP, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. *Ann Rheum Dis* 2013; 72(Suppl3):744.
7. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, **Beukelman T**, Winthrop KL, Baddley JW, Muntner P, Curtis JR. Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. *Ann Rheum Dis* 2013; 72(Suppl3):553.
8. **Beukelman T**, Xie F, Baddley J, Chen L, Delzell E, Grijalva C, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Arthritis Rheum* 2012; 64 Suppl 10:S329.
9. Weiss JE, Morgan DeWitt EM, **Beukelman T**, Schanberg LE, Schneider R, Kimura Y. Choice of systemic JIA treatment among Childhood Arthritis and Rheumatology Research Alliance (CARRA) rheumatologists. *Arthritis Rheum* 2012; 64 Suppl 10:S492.

10. Luca N, Burnett H, Ungar W, **Beukelman T**, Feldman BM, Schwartz G, Bayoumi A. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. *Arthritis Rheum* 2012; 64 Suppl 10:S501.
11. Curtis JR, Chen L, **Beukelman T**, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. *Arthritis Rheum* 2012; 64 Suppl 10:S401.
12. Cron RQ, Zhang M, Bemrich-Stolz CJ, **Beukelman T**. Rapid and effective response to immunosuppression in treating macrophage activation syndrome associated with a heterozygous dominant negative mutation in RAB27a leading to decreased cytolytic activity. *Arthritis Rheum* 2012; 64 Suppl 10:S1125.
13. Bingham CA, Darbie LM, Marsolo K, Weiss JE, Ardoin SP, Laxer RM, Lovell DJ, Passo MH, Vora S, Gottlieb BS, **Beukelman T**, Griffin N, Stock JA, Miller ML, Onel K, Ronis T, Margolis P, Morgan DeWitt EM. Improving delivery of care for JIA across a multi-center network using a shared data registry and quality improvement science: The Pediatric Rheumatology Care and Outcomes Improvement Network. *Arthritis Rheum* 2012; 64 Suppl 10:S1101.
14. **Beukelman T**, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Pharmacoepidemiol Drug Saf* 2012; 21 Suppl 3:S45.
15. Curtis JR, Chen L, **Beukelman T**, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a national arthritis cohort with medicare administrative claims data. *Pharmacoepidemiol Drug Saf* 2012; 21 Suppl 3:S46.
16. **Beukelman T**, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. DMARD use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. *Ann Rheum Dis* 2012; 71(Suppl3):438.
17. **Beukelman T**, Xie F, Baddley JW, Chen L, Delzell E, Grijalva C, Patkar N, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Ann Rheum Dis* 2012; 71 (Suppl3):270.
18. **Beukelman T**, Bingham CA, Gottlieb BS, Griffin N, Laxer R, Marsolo K, Passo MH, Lannon C, Margolis P, DeWitt EM. Increasing quality of JIA treatment: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN). *Ann Rheum Dis* 2012; 71(Suppl3):706.
19. **Beukelman T**, Ringold S, Davis T, Morgan DeWitt E, Pelajo CF, Weiss P, Kimura Y. Utilization of biologic and non-biologic disease modifying anti-rheumatic drugs in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. *Arthritis Rheum* 2011; 63 Suppl 10:S104.
20. Weiss P, **Beukelman T**, Schanberg LE, Kimura Y, Colbert RA. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis-specific pain across juvenile idiopathic arthritis (JIA) categories: Preliminary analyses from the CARRA-net Registry. *Arthritis Rheum* 2011; 63 Suppl 10:S105.
21. Morgan DeWitt E, **Beukelman T**, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Ilowite NT, Wallace CA, Kimura Y. Development of consensus treatment plans for

- new-onset systemic juvenile idiopathic arthritis. *Arthritis Rheum* 2011; 63 Suppl 10:S106.
22. Miller M, **Beukelman T**, Lales G, McKenna S, Ruprecht J, Curran ML, Klein-Gitelman MS. Application and examination of the key clinical parameters from the 2011 ACR recommendations for the treatment of JIA using electronic medical record-derived data from a clinical cohort. *Arthritis Rheum* 2011; 63 Suppl 10:S98.
 23. Morgan DeWitt E, **Beukelman T**, Gottlieb BS, Griffin N, Kimura Y, Barnes I, Passo MH. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. *Arthritis Rheum* 2011; 63 Suppl 10:S803-4.
 24. Grijalva C, Chen L, Delzell E, Baddley J, **Beukelman T**, Winthrop K, Griffin M, Herrinton, Liu L, Nourjah P, Patkar NM, Solomon DH, Lewis J, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalization for infection in patients with autoimmune diseases. *Arthritis Rheum* 2011; 63 Suppl 10:S316.
 25. **Beukelman T**, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment [abstract]. *Pharmacoepidemiol Drug Saf* 2011; 20 Suppl 1:S13.
 26. Grijalva CG, Chen L, Delzell E, Baddley JW, **Beukelman T**, Griffin MR, Herrinton L, Liu L, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Winthrop KL, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalized bacterial infections in patients with rheumatoid arthritis. *Pharmacoepidemiol Drug Saf* 2011; 20 Suppl 1:S182.
 27. Curtis J, Xie F, Chen L, **Beukelman T**, Saag K, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents [abstract]. *Ann Rheum Dis* 2011.
 28. **Beukelman T**, Haynes K, Curtis JR, Xie F, Chen L, Delzell E, Kim H, Saag KG, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S871
 29. **Beukelman T**, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S879-80.
 30. **Beukelman T**, Xie F, Curtis JR. Usage of TNF α inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S100-1.
 31. Curtis JR, Xie F, Chen L, Baddley J, **Beukelman T**, Saag KG, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S300-1
 32. **Beukelman T**, Xie F, Chen L, Baddley J, Delzell E, Grijalva, Patkar NM, Saag KG, Winthrop K, Curtis JR. Characteristics of cases of PML among patients with selected rheumatic and autoimmune diseases [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S300.
 33. Winthrop KL, Baddley J, Chen L, Liu L, Grijalva CG, Patkar NM, Xie F, Delzell E, **Beukelman T**, Herrinton LJ, Saag KG, Curtis JR. Rates of tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients who use anti-

- tumor necrosis factor alpha therapy; from the SAFety of Biologic ThERapy (SABER) study [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S170.
34. Record JL, **Beukelman T**, Cron RQ. High prevalence of inflammatory myositis in patients with pediatric systemic lupus erythematosus in a US southeastern state [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S700.
 35. Sharpe T, Good J, **Beukelman T**, Waite PD, Cron RQ. Benefit of intra-articular corticosteroid injections by oral and maxillofacial surgery treating temporomandibular joint arthritis in children with juvenile idiopathic arthritis [abstract]. *Arthritis Rheum* 2010; 62 Suppl 10:S90.
 36. Cron RQ, **Beukelman T**, Bemrich-Stolz C, Watts RG. IL-1 antagonism for treatment of macrophage activation syndrome [abstract]. *Pediatr Blood Cancer* 2011; 56:701.
 37. Cron RQ, Genin A, Brunner M, Scalzi LV, Mishra N, **Beukelman T**, Mehta J. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis [abstract]. *J Immunol* 2010; 184:135.4.
 38. **Beukelman T**, Delzell E, Saag KG. The risk of serious infection in juvenile idiopathic arthritis [abstract]. *Clin Transl Sci* 2010; 3:S8.
 39. Morgan Dewitt E, Passo M, Kimura Y, **Beukelman T**, Gottlieb B, Margolis P. Pediatric rheumatology improvement network for clinical excellence and safety—PRINCES [abstract]. *Arthritis Rheum* 2009; 60 Suppl 10:S705.
 40. **Beukelman T**, Saag KG, Curtis JR, Nair R, Kilgore ML, Pisu M. The cost-effectiveness of a multi-modal intervention for the prevention of glucocorticoid-induced osteoporosis [abstract]. *Arthritis Rheum* 2008; 58 Suppl 9:S739.
 41. Cron RQ, **Beukelman T**, Reed AB, Behrens EM. IL-1 antagonism for treatment of macrophage activation syndrome [abstract]. *Arthritis Rheum* 2008; 58 Suppl 9:S247-8.
 42. **Beukelman T**, Guevara J, Albert DA. Outcomes in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: Results of a decision analysis model [abstract]. *Arthritis Rheum* 2007; 56 Suppl 9:S136.
 43. **Beukelman T**, Guevara J, Albert DA, Sherry DD, Burnham J. Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada [abstract]. *Arthritis Rheum* 2006; 54:4030.
 44. Behrens E, **Beukelman T**, Gallo L, Spangler J, Rosenkrantz M, Arkachaisri T, et al. Pennsylvania systemic onset juvenile arthritis registry (PASOJAR): presenting characteristics and demographic data of a large cohort [abstract]. *Arthritis Rheum* 2006; 54:4057.
 45. Behrens E, **Beukelman T**, Paessler M, Cron RQ. Occult macrophage activation syndrome in systemic juvenile idiopathic arthritis [abstract]. *Arthritis Rheum* 2006; 54 Suppl 9:S695.
 46. **Beukelman T**, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intra-articular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis [abstract]. *Arthritis Rheum* 2005; 52 Suppl 9:S85.
 47. Behrens E, **Beukelman T**, Tustin N, Cron RQ, Pessler F. Secondary hemophagocytic lymphohistiocytosis: Is there a role for Interleukin-1 blockade? [abstract]. *Clin Immunol* 2005; 116:298-9.

Poster Exhibits

1. Mannion M, Xie F, Curtis JR, **Beukelman T**. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the U.S. and the influence of TNF inhibitors. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.
2. Chen L, **Beukelman T**, Bharat A, Xie F, Saag KG, Delzell E, Curtis JR. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.
3. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, **Beukelman T**, Winthrop K. Comparative risks of recurrent hospitalized infection association with biologics in RA patients at high risk. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.
4. Cron RQ, Tramballi A, **Beukelman T**, Weiser P, Atkinson TP, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. Annual European Congress of Rheumatology, 2013.
5. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, **Beukelman T**, Winthrop KL, Baddley JW, Munter P, Curtis JR. Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. Annual European Congress of Rheumatology, 2013.
6. Luca N, Burnett H, Ungar W, **Beukelman T**, Feldman BM, Schwartz G, Bayoumi A. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2012.
7. Weiss JE, Morgan DeWitt EM, **Beukelman T**, Schanberg LE, Schneider R, Kimura Y. Choice of systemic JIA treatment among Childhood Arthritis and Rheumatology Research Alliance (CARRA) rheumatologists. American College of Rheumatology Annual Scientific Meeting, 2012.
8. Curtis JR, Chen L, **Beukelman T**, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. American College of Rheumatology Annual Scientific Meeting, 2012.
9. **Beukelman T**, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2012.
10. Curtis JR, Chen L, **Beukelman T**, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a national arthritis cohort with medicare administrative claims data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2012.
11. **Beukelman T**, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. DMARD use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Annual European Congress of Rheumatology, 2012.
12. **Beukelman T**, Xie F, Baddley JW, Chen L, Delzell E, Grijalva C, Patkar N, Saag KG, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Annual European Congress of Rheumatology, 2012.
13. **Beukelman T**, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. University of Alabama at Birmingham Center for Clinical and Translational Science Third Annual Scientific Symposium, 2011.

14. **Beukelman T**, Ringold S, Davis T, Morgan DeWitt E, Pelajo CF, Weiss P, Kimura Y. Utilization of biologic and non-biologic disease modifying anti-rheumatic drugs in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. American College of Rheumatology Annual Scientific Meeting, 2011.
15. Weiss P, **Beukelman T**, Schanberg LE, Kimura Y, Colbert RA. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis-specific pain across juvenile idiopathic arthritis (JIA) categories: Preliminary analyses from the CARRA-net Registry. American College of Rheumatology Annual Scientific Meeting, 2011.
16. Morgan DeWitt E, **Beukelman T**, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Ilowite NT, Wallace CA, Kimura Y. Development of consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2011.
17. Miller M, **Beukelman T**, Lales G, McKenna S, Ruprecht J, Curran ML, Klein-Gitelman MS. Application and examination of the key clinical parameters from the 2011 ACR recommendations for the treatment of JIA using electronic medical record-derived data from a clinical cohort. American College of Rheumatology Annual Scientific Meeting, 2011.
18. Morgan DeWitt E, **Beukelman T**, Gottlieb BS, Griffin N, Kimura Y, Barnes I, Passo MH. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. American College of Rheumatology Annual Scientific Meeting, 2011.
19. Baddley JW, Winthrop KL, Grijalva CG, Chen L, Xie F, Delzell E, **Beukelman T**, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Saag KG, Curtis JR. Risk of non-mycobacterial opportunistic infections in new users of TNF inhibitor therapy: Results of the Safety Assessment of Biological Therapy study. Infectious Diseases Society of America Annual Meeting, 2011.
20. Baddley JW, Winthrop KL, Patkar NM, Delzell E, Xie F, Chen L, **Beukelman T**, Curtis JR. Incidence and risk factors for cryptococcosis in older Americans. Infectious Diseases Society of America Annual Meeting, 2011.
21. Grijalva CG, Chen L, Delzell E, Baddley JW, **Beukelman T**, Griffin MR, Herrinton L, Liu L, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Winthrop KL, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalized bacterial infections in patients with rheumatoid arthritis. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2011.
22. Ringold S, **Beukelman T**, Morgan DeWitt E, Natter M, Nigrovic PA, Kimura Y. Disease characteristics and medications use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): Preliminary analyses from the CARRAnet registry. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.
23. Morgan DeWitt E, **Beukelman T**, Gottlieb BS, Griffin N, Kimura Y, McNiff K, Passo M. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.
24. Morgan DeWitt E, **Beukelman T**, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Wallace CA, Kimura Y. Development of consensus best treatment plans for new-

- onset systemic juvenile idiopathic arthritis. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.
25. Cron RQ, Fain E, Atkinson G, Weiser P, **Beukelman T**. Temporomandibular joint arthritis in patients with non-JIA childhood arthritis. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.
 26. Curtis J, Xie F, Chen L, **Beukelman T**, Saag K, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents. Annual European Congress of Rheumatology, 2011.
 27. **Beukelman T**, Xie F, Curtis JR. Usage of TNF α inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database. American College of Rheumatology Annual Scientific Meeting, 2010.
 28. Winthrop KL, Baddley J, Chen L, Liu L, Grijalva CG, Patkar NM, Xie F, Delzell E, **Beukelman T**, Herrinton LJ, Saag KG, Curtis JR. Rates of tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients who use anti-tumor necrosis factor alpha therapy; from the SAfety of Biologic ThERapy (SABER) study. American College of Rheumatology Annual Scientific Meeting, 2010.
 29. Record J, **Beukelman T**, Cron RQ. High prevalence of inflammatory myositis in patients with pediatric systemic lupus erythematosus in a US southeastern state. American College of Rheumatology Annual Scientific Meeting, 2010.
 30. Sharpe T, Good J, **Beukelman T**, Waite PD, Cron RQ. Benefit of intra-articular corticosteroid injections by oral and maxillofacial surgery treating temporomandibular joint arthritis in children with juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2010.
 31. Cron RQ, **Beukelman T**, Bemrich-Stolz C, Watts RG. IL-1 antagonism for treatment of macrophage activation syndrome. Histiocyte Society Annual Scientific Meeting, 2010.
 32. Cron RQ, Genin A, Brunner M, Scalzi LV, Mishra N, **Beukelman T**, Mehta J. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis. American Association of Immunologists Annual Meeting, 2010.
 33. **Beukelman T**, Saag KG, Curtis JR, Nair R, Kilgore ML, Pisu M. The Cost-Effectiveness of a Multi-modal Intervention for the Prevention of Glucocorticoid-Induced Osteoporosis. American College of Rheumatology Annual Scientific Meeting, 2008.
 34. Cron RQ, **Beukelman T**, Reed AB, Behrens EM. IL-1 antagonism for treatment of macrophage activation syndrome. American College of Rheumatology Annual Scientific Meeting, 2008.
 35. Donnithorne K, Cron RQ, **Beukelman T**. Treatment with tumor necrosis factor alpha inhibitors in early versus established juvenile idiopathic arthritis. UAB Medical Student Research Day, 2008.
 36. **Beukelman T**, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. American College of Rheumatology Keystone Pediatric Rheumatology Symposium, 2008.
 37. Mehta J, Genin A, Brunner M, **Beukelman T**, Scalzi LV, Mishra N, Cron RQ. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased NFAT activity, NFAT c1 levels, and glomerulonephritis. American College of Rheumatology Keystone Pediatric Rheumatology Symposium, 2008. [oral presentation]

38. **Beukelman T**, Guevara J, Albert DA. Outcomes in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: Results of a decision analysis model. American College of Rheumatology Annual Scientific Meeting, 2007.
39. **Beukelman T**, Guevara J, Albert DA, Sherry DD, Burnham J. Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada. American College of Rheumatology Annual Scientific Meeting, 2006. [oral presentation]
40. Behrens E, **Beukelman T**, Gallo L, Spangler J, Rosenkrantz M, Arkachaisri T, et al. Pennsylvania systemic onset juvenile arthritis registry (PASOJAR): presenting characteristics and demographic data of a large cohort. American College of Rheumatology Annual Scientific Meeting, 2006.
41. Behrens E, **Beukelman T**, Paessler M, Cron RQ. Occult macrophage activation syndrome in systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2006.
42. **Beukelman T**, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intra-articular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2005.
43. Behrens E, **Beukelman T**, Tustin N, Cron RQ, Pessler F. Secondary hemophagocytic lymphohistiocytosis: Is there a role for Interleukin-1 blockade? Clinical Immunology Society Primary Immunodeficiency Diseases Consortium Conference, 2005.

Oral Presentations

Scientific papers presented at national and international meetings:

1. “Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the United States and the influence of TNF inhibitors”, Abstract Session, Annual European Congress of Rheumatology, Madrid, Spain, June 2013.
2. “Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2012.
3. “Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment”, Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, August 2011.
4. “Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data”, Plenary Abstract Session, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.
5. “2010 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis”, Clinical Symposium, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.
6. “Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.
7. “Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada”, Concurrent Abstract Session,

American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2006.

Scientific papers presented at local and regional meetings: None

Invited workshops: None

Invited lectures at local and regional courses and meetings:

1. "Usage and Safety of TNF Inhibitors in the Treatment of Juvenile Idiopathic Arthritis". ACR/EULAR Exchange Program, Charité-University Medicine Berlin, Berlin, Germany, June 2013.
2. "Usage and Safety of TNF Inhibitors in the Treatment of Juvenile Idiopathic Arthritis". ACR/EULAR Exchange Program, Karolinska Institute, Stockholm, Sweden, June 2013.
3. "Malignancy and Juvenile Idiopathic Arthritis: What is the Risk?". University of Toronto/Hospital for Sick Children Pediatric Rheumatology Meeting, Toronto, Canada, September 2011.
4. "The Risk of Serious Infection and Malignancy in Juvenile Idiopathic Arthritis and Its Treatment". AHRQ Centers for Education and Research on Therapeutics Scientific Conference, December 2010.
5. "The Risk of Infection and Malignancy in Juvenile Idiopathic Arthritis: Investigating the Incidence of Adverse Events Using Medicaid Administrative Claims Data". University of Alabama at Birmingham Center for Clinical and Translational Science Second Annual Scientific Symposium, November 2010.
6. "Laboratory Testing in Pediatric Rheumatic Disease", Educational Update for Pediatric Allergy, Immunology, and Rheumatology, Children's Hospital of Alabama, February 2009.
7. "Intra-articular Glucocorticoid Injections in the Treatment of Juvenile Idiopathic Arthritis", The 53rd Annual Lowe Conference on Rheumatic Disease, Nauvoo, AL, October 2008.
8. "Medication Update", Arthritis Foundation Juvenile Arthritis Family Day, Philadelphia, April, 2006.
9. "A Pediatric Rheumatologist's View of Chronic Interstitial Lung Disease, Pulmonary Hypertension, and Pulmonary Capillaritis", Pediatric Rheumatology Grand Rounds, The Children's Hospital of Philadelphia, September, 2005.
10. "Immunosuppression and Infection in Rheumatic Disease", Pediatric Rheumatology Grand Rounds, The Children's Hospital of Philadelphia, April, 2005.
11. "The Hemophagocytic Syndrome", Pediatric Rheumatology Grand Rounds, The Children's Hospital of Philadelphia, December, 2004.
12. "Juvenile Fibromyalgia", Chairman's Rounds, Cincinnati Children's Hospital Medical Center, August, 2003.

Lay Press

[Covering the published manuscript: **Beukelman T**, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment. *Arthritis Rheum.* [accepted 17 Feb 2012]]

1. Walsh, N. Infection risk high in juvenile arthritis. Medpage today 2012 May 1.
<http://www.medpagetoday.com/Rheumatology/Arthritis/32434>

[Covering the published manuscript: **Beukelman T**, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012; 64:1263-7.]

1. Carollo, K. Juvenile idiopathic arthritis may raise kids' cancer risk. ABCnews.com 2012 Feb 13. <http://abcnews.go.com/Health/juvenile-idiopathic-arthritis-linked-elevated-cancer-risk-study/story?id=15559238>
2. Hansen, J. Medical detectives: UAB researchers, colleagues probe the case of juvenile arthritis drug side effect. The Birmingham News 2012 Feb 16: E1,4.
http://www.al.com/living/index.ssf/2012/02/uab_researcher_colleagues_prob.html
3. Bankhead, C. Arthritis in kids may raise cancer risk. Medpage today 2012 Feb 13.
<http://www.medpagetoday.com/Rheumatology/Arthritis/31142>
4. Boyles, S. Cancer risk higher for kids with arthritis: Medications used to treat condition likely not to blame. WebMD 2012 Feb 13. <http://www.webmd.com/rheumatoid-arthritis/news/20120213/cancer-risk-higher-kids-with-arthritis>
5. Picard, A. Good news/bad news for kids with juvenile arthritis. The Globe and Mail 2012 Feb 13. <http://m.theglobeandmail.com/life/health/new-health/conditions/cancer/other-cancers/good-newsbad-news-for-kids-with-juvenile-arthritis/article2336468/?service=mobile>
6. Williams, L. Juvenile arthritis patient risk for cancer highlighted. MedWire News 2012 Feb 13. http://www.medwire-news.md/46/97511/Oncology/Juvenile_arthritis_patient_risk_for_cancer_highlighted.html
7. Mitchell, M. Juvenile arthritis and cancer risk, what parents should know. EmaxHealth 2012 Feb 13. <http://www.emaxhealth.com/1275/juvenile-arthritis-and-cancer-risk-what-parents-should-know>
8. Davis, JL. More evidence reveals JIA treatment isn't cause of cancer risk. *Arthritis Today* 2012 Feb 13. <http://www.arthritistoday.org/news/juvenile-arthritis-treatment-cancer-risk179.php>
9. Harding, A. TNF drugs for juvenile arthritis don't boost malignancies. Reuters Health 2012 March 16.
10. Moon, M. Cancer rate higher in JIA, regardless of therapy. *Rheumatology News* 2012 March:11.

[Covering the published manuscript: **Beukelman T**, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. *Arthritis Care Res* 2011; 63:465-82.]

1. Walsh, N. New JIA treatment recommendations published. Medpage Today 2011 April 1. <http://www.medpagetoday.com/Rheumatology/Arthritis/25662>
2. Kelly, J. First ACR advice for juvenile idiopathic arthritis treatment. Medscape News 2011 April 4. <http://www.medscape.com/viewarticle/740148>
3. Rothman Schonfeld, A. JIA guidelines reflect treatment advances. *Rheumatology News* 2011 April:1,18-9.

4. Rothman Schonfeld, A. Systemic JIA guidelines urged early treatment. Rheumatology News 2011 April: 8,19.
5. Holliman, K. New guidance for rheumatologists who treat JIA. The Rheumatologist 2011 April: 60-2.
6. Eustice, C. ACR recommendations for the treatment of juvenile idiopathic arthritis. About.com 2011 April 14. <http://arthritis.about.com/b/2011/04/24/acr-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis.htm>
7. Walker, T. New treatment guidelines strongly endorse use of biologic agents for many children with arthritis refractory to methotrexate. Formulary 2011 May: 157-8.

[Covering the scientific meeting abstract: **Beukelman T**, Haynes K, Curtis JR, Xie F, Chen L, Delzell E, Kim H, Saag KG, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. Arthritis Rheum 2010;62 Suppl 10:S871]

1. Splete, H. Cancer risk doubled in children with JIA. Rheumatology News 2011 Jan:24. <http://www.internalmedicineneews.com/single-view/cancer-risk-doubled-in-children-with-jia/a15edc493b.html>
2. Davis, J. Study shows no link to TNF inhibitors and cancer in JIA. Arthritis Today 2010. <http://www.arthritistoday.org/news/anti-tnf-biologics-juvenile-arthritis-cancer102.php>

[Covering the published manuscript: **Beukelman T**, Guevara JP, Albert DA. Optimal treatment of knee monoarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580-88.]

1. Axtell, B. Steroid injection first, best for knee. Kid's Get Arthritis Too 2008 Jan/Feb:7.

[Covering the development of a new Pediatric Rheumatology clinic at the University of Alabama at Birmingham/Children's Hospital of Alabama.]

1. Valesco, A. Specialists in juvenile arthritis start at Children's. Birmingham News 2007 Sept 12. http://blog.al.com/spotnews/2007/09/specialists_in_juvenile_arthri.html
2. Lockridge, D. Pediatric rheumatology comes to Birmingham. Birmingham Medical News 2007 Dec. <http://www.birminghammedicalnews.com/news.php?viewStory=1044>
3. Valesco, A. Center celebrates second birthday, addition of third doctor for children with arthritis. Birmingham News 2009 Sept 10. <http://www.al.com/news/birminghamnews/metro.ssf?/base/news/1252570531170670.xml&coll=2>